Dementia With Lewy Bodies Clinical Trials 2023

Browse 34 Dementia With Lewy Bodies Medical Studies Across 122 Cities

1 Phase 3 Trial · 210 Dementia With Lewy Bodies Clinics

Reviewed by Michael Gill, B. Sc.
10 Dementia With Lewy Bodies Clinical Trials Near Me
Top Hospitals for Dementia With Lewy Bodies Clinical Trials
Image of Mayo Clinic in Minnesota.
Mayo Clinic
Rochester
4Active Trials
10All Time Trials for Dementia With Lewy Bodies
2008First Dementia With Lewy Bodies Trial
Image of University of Pennsylvania in Pennsylvania.
University of Pennsylvania
Philadelphia
3Active Trials
6All Time Trials for Dementia With Lewy Bodies
2016First Dementia With Lewy Bodies Trial
Image of University of California, San Francisco in California.
University of California, San Francisco
San Francisco
3Active Trials
5All Time Trials for Dementia With Lewy Bodies
2015First Dementia With Lewy Bodies Trial
Image of University of Florida in Florida.
University of Florida
Gainesville
2Active Trials
3All Time Trials for Dementia With Lewy Bodies
2019First Dementia With Lewy Bodies Trial
Image of MD Stem Cells in Connecticut.
MD Stem Cells
Westport
2Active Trials
2All Time Trials for Dementia With Lewy Bodies
2016First Dementia With Lewy Bodies Trial
Top Cities for Dementia With Lewy Bodies Clinical Trials
Image of Chicago in Illinois.
Chicago
8Active Trials
Alzheimer's Association Head OfficeTop Active Site
Image of Rochester in Minnesota.
Rochester
7Active Trials
Mayo ClinicTop Active Site
Dementia With Lewy Bodies Clinical Trials by Phase of TrialDementia With Lewy Bodies Clinical Trials by Age GroupMost Recent Dementia With Lewy Bodies Clinical TrialsTop Treatments for Dementia With Lewy Bodies Clinical Trials
Treatment Name
Active Dementia With Lewy Bodies Clinical Trials
All Time Trials for Dementia With Lewy Bodies
First Recorded Dementia With Lewy Bodies Trial
Intervention
1
1
2023
VOCALE LBD+
1
1
2023
123I-MIBG scintigraphy
1
1
2023
Intervention arm
1
1
2023
Tele-neurohub
1
1
2022
Recently Completed Studies with FDA Approved Treatments for Dementia With Lewy Bodies
Treatment
Year
Sponsor
E2027
2021
Eisai Inc.

What Are Dementia With Lewy Bodies Clinical Trials?

Dementia with Lewy Bodies, or DLB, is one of the many types of progressive dementia. The condition is characterized by a decline in reasoning, independent functioning, and thinking. 

Symptoms include recurring visual hallucinations, cognition fluctuation, REM sleep disorder, memory loss, and nervous system malfunction.

DLB is linked to abnormal brain protein deposits (alpha-synuclein), also called Lewy Bodies. They affect the brain’s chemicals leading to problems with movement, mood, thinking, and behavior. 

Dementia with Lewy Bodies clinical trials are designed to understand the disease development in patients, its impact, and the best ways to treat the condition. These aim to understand the progression of the disease in patients. 

Why Is Dementia with Lewy Bodies Being Studied Through Clinical Trials?

DLB is the second most common type of dementia affecting over 1.4 million people in the US. The symptoms of Dementia with Lewy Bodies mostly appear in people above 50 years old. However, it can affect younger people too. The survival rate is about five to seven years after being diagnosed with DLB. The condition accounts for nearly five percent of dementia cases in old individuals.

Dementia with Lewy Bodies clinical trials are underway to identify the specific cause and cure. Researchers continue to study DLB through trials to find treatments that can slow and stop the brain’s cell damage and prolong the patients’ life.

What Are the Types of Treatments Available for Dementia with Lewy Bodies?

As no cure or prevention treatment is available, the plan revolves around managing symptoms of DLB and identifying ways to make daily tasks easier. Hence, treatments help improve the quality of life of patients with Dementia with Lewy Bodies, not cure the disease.

For example, a Cholinesterase inhibitor is an effective drug for managing changes in thinking. It can also help with DLB symptoms. Other medications may include antidepressants.

What Are Some Recent Breakthrough Clinical Trials for?

2021: New evidence on the management of Lewy body dementia-The study summarizes new evidence for non-pharmacological and pharmacological management of DLB. It shows that instead of isolating treatments for symptoms at the cost of another, an interdisciplinary approach should be used for the best therapeutic gains.

2016: The Case for Antipsychotics in Dementia with Lewy Bodies- The report shows hallucination is a common symptom in patients with DLB. However, atypical antipsychotic drugs should be avoided because of adverse reactions. However, more research is needed to determine a better alternative to antipsychotics in DLB patients.

Who Are Some of the Key Opinion Leaders/Researchers/Institutions Conducting Clinical Trial Research?

Lewy Body Dementia Research Center of Excellence

It is a comprehensive and first-ever research center to perform Dementia with Lewy Bodies research and clinical trials. It aims to streamline DLB science while helping patients and families.

Columbia University Irving Medical Center

It is a non-profit strongly committed to supporting patients, increasing awareness, and assisting DLB scientific advances.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 1st, 2021

Last Reviewed: August 1st, 2023

References1 Johnstone DM, Moro C, Stone J, Benabid AL, Mitrofanis J. Turning On Lights to Stop Neurodegeneration: The Potential of Near Infrared Light Therapy in Alzheimer's and Parkinson's Disease. Front Neurosci. 2016 Jan 11;9:500. doi: 10.3389/fnins.2015.00500. eCollection 2015. Review. https://pubmed.ncbi.nlm.nih.gov/267930492 Johnstone DM, Moro C, Stone J, Benabid AL, Mitrofanis J. Turning On Lights to Stop Neurodegeneration: The Potential of Near Infrared Light Therapy in Alzheimer's and Parkinson's Disease. Front Neurosci. 2016 Jan 11;9:500. doi: 10.3389/fnins.2015.00500. eCollection 2015. https://pubmed.ncbi.nlm.nih.gov/267930493 Sardi SP, Clarke J, Viel C, Chan M, Tamsett TJ, Treleaven CM, Bu J, Sweet L, Passini MA, Dodge JC, Yu WH, Sidman RL, Cheng SH, Shihabuddin LS. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3537-42. doi: 10.1073/pnas.1220464110. Epub 2013 Jan 7. https://pubmed.ncbi.nlm.nih.gov/232972264 Possin KL, Merrilees JJ, Dulaney S, Bonasera SJ, Chiong W, Lee K, Hooper SM, Allen IE, Braley T, Bernstein A, Rosa TD, Harrison K, Begert-Hellings H, Kornak J, Kahn JG, Naasan G, Lanata S, Clark AM, Chodos A, Gearhart R, Ritchie C, Miller BL. Effect of Collaborative Dementia Care via Telephone and Internet on Quality of Life, Caregiver Well-being, and Health Care Use: The Care Ecosystem Randomized Clinical Trial. JAMA Intern Med. 2019 Dec 1;179(12):1658-1667. doi: 10.1001/jamainternmed.2019.4101. https://pubmed.ncbi.nlm.nih.gov/315666515 Hebron ML, Lonskaya I, Moussa CE. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models. Hum Mol Genet. 2013 Aug 15;22(16):3315-28. doi: 10.1093/hmg/ddt192. Epub 2013 May 10. https://pubmed.ncbi.nlm.nih.gov/236665286 Narita A, Shirai K, Itamura S, Matsuda A, Ishihara A, Matsushita K, Fukuda C, Kubota N, Takayama R, Shigematsu H, Hayashi A, Kumada T, Yuge K, Watanabe Y, Kosugi S, Nishida H, Kimura Y, Endo Y, Higaki K, Nanba E, Nishimura Y, Tamasaki A, Togawa M, Saito Y, Maegaki Y, Ohno K, Suzuki Y. Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study. Ann Clin Transl Neurol. 2016 Feb 2;3(3):200-15. doi: 10.1002/acn3.292. eCollection 2016 Mar. https://pubmed.ncbi.nlm.nih.gov/270426807 Mullin S, Smith L, Lee K, D'Souza G, Woodgate P, Elflein J, Hallqvist J, Toffoli M, Streeter A, Hosking J, Heywood WE, Khengar R, Campbell P, Hehir J, Cable S, Mills K, Zetterberg H, Limousin P, Libri V, Foltynie T, Schapira AHV. Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. JAMA Neurol. 2020 Apr 1;77(4):427-434. doi: 10.1001/jamaneurol.2019.4611. https://pubmed.ncbi.nlm.nih.gov/319303748 Mullin S, Smith L, Lee K, D'Souza G, Woodgate P, Elflein J, Hällqvist J, Toffoli M, Streeter A, Hosking J, Heywood WE, Khengar R, Campbell P, Hehir J, Cable S, Mills K, Zetterberg H, Limousin P, Libri V, Foltynie T, Schapira AHV. Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. JAMA Neurol. 2020 Apr 1;77(4):427-434. doi: 10.1001/jamaneurol.2019.4611. https://pubmed.ncbi.nlm.nih.gov/319303749 Cella D, Lai JS, Nowinski CJ, Victorson D, Peterman A, Miller D, Bethoux F, Heinemann A, Rubin S, Cavazos JE, Reder AT, Sufit R, Simuni T, Holmes GL, Siderowf A, Wojna V, Bode R, McKinney N, Podrabsky T, Wortman K, Choi S, Gershon R, Rothrock N, Moy C. Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neurology. 2012 Jun 5;78(23):1860-7. doi: 10.1212/WNL.0b013e318258f744. Epub 2012 May 9. https://pubmed.ncbi.nlm.nih.gov/2257362610 Weiss JN, Levy S. Neurologic Stem Cell Treatment Study (NEST) using bone marrow derived stem cells for the treatment of neurological disorders and injuries: study protocol for a nonrandomized efficacy trial. Clin Trials Degener Dis. 2016 [cited 2019 Jun 18];1:176-80.